LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Edwards Lifesciences Corp

Gesloten

SectorGezondheidszorg

87.66 1.95

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

85.72

Max

88.3

Belangrijke statistieken

By Trading Economics

Inkomsten

290M

381M

Verkoop

79M

1.6B

K/W

Sectorgemiddelde

47.654

49.888

EPS

0.78

Winstmarge

23.092

Werknemers

16,000

EBITDA

382M

515M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.27% upside

Dividenden

By Dow Jones

Volgende Winsten

23 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.5B

51B

Vorige openingsprijs

85.71

Vorige sluitingsprijs

87.66

Edwards Lifesciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jan 2026, 00:16 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Drops Merger With JenaValve

6 aug 2025, 18:44 UTC

Acquisities, Fusies, Overnames

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Peer Vergelijking

Prijswijziging

Edwards Lifesciences Corp Prognose

Koersdoel

By TipRanks

14.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 98.27 USD  14.27%

Hoogste 110 USD

Laagste 85 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Edwards Lifesciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

15

Buy

3

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat